|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute of Mental Health (NIMH) Duke University |
| Information provided by: | National Institute of Mental Health (NIMH) |
| ClinicalTrials.gov Identifier: | NCT00045773 |
Purpose
This 12-week study will evaluate the effectiveness of sertraline (Zoloft®) for treatment of depression associated with small vascular lesions in the brain (vascular depression).
| Condition | Intervention |
|
Depressive Disorder Depression |
Drug: Sertraline |
| MedlinePlus related topics: | Depression |
| Drug Information available for: | Sertraline hydrochloride Sertraline |
| Study Type: | Observational |
| Study Design: | Case-Only, Prospective |
| Official Title: | Treatment Outcome of Vascular Depression |
| Enrollment: | 208 |
| Study Start Date: | April 2001 |
| Study Completion Date: | April 2006 |
| Primary Completion Date: | April 2006 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
| 1 |
Drug: Sertraline
50 - 200mg, once per day for 12 weeks.
|
Major late life depression (LLD) is an important health problem with a large and growing number of affected individuals. A significant subset of patients with LLD, particularly those with vascular depression, have abnormalities in certain parts of the brain that are evident on MRI scans and may be associated with poor acute and long-term response to antidepressant treatment. Studies have also indicated that LLD patients frequently have frontal lobe dysfunction. A longitudinal study with the antidepressant nortriptyline has demonstrated that frontal lobe dysfunction is associated with poor acute response and a greater risk for recurrence of LLD. However, it is not known if this finding applies to other antidepressants. This study will be the first clinical trial to simultaneously test the effects of specific brain and psychological factors on course of response, remission rate, and other measures of health outcomes in people with LLD.
Participants are treated with sertraline for 12 weeks. During this period, participants undergo cognitive testing, MRI, electrocardiogram (EKG), and laboratory tests. Study visits occur every 2 weeks.
Eligibility
| Ages Eligible for Study: | 60 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Adults 60+ with major depression.
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Missouri | |||||
| Washington University School of Medicine | |||||
| St. Louis, Missouri, United States, 63110 | |||||
| United States, North Carolina | |||||
| Duke University Medical Center | |||||
| Durham, North Carolina, United States, 27710 | |||||
| National Institute of Mental Health (NIMH) |
| Duke University |
| Principal Investigator: | Yvette I. Sheline, M.D. | Washington University Psychiatrist |
| Principal Investigator: | Murali Doraiswamy, M.D. | Duke University |
More Information
Volunteer for Health with Washington University School of Medicine 
  |
Washington University School of Medicine Psychiatry Department 
  |
|
Sheline YI, Black KJ, Lin DY, Christensen GE, Gado MH, Brunsden BS, Vannier MW. Stereological MRI volumetry of the frontal lobe. Psychiatry Res. 1996 Oct 7;67(3):203-14.
  |
|
Sheline Y, Loenze E, Cross D, et al., (1996) Quantifying white matter lesions in elderly women with depression. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico.
  |
|
Sheline YI, Freedland KE, Carney RM. How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med. 1997 Jan;102(1):54-9. Review.
  |
| Responsible Party: | Washington University ( Yvette I. Sheline, MD ) |
| Study ID Numbers: | R01 MH60697, DATR A4-GPX |
| First Received: | September 9, 2002 |
| Last Updated: | November 10, 2008 |
| ClinicalTrials.gov Identifier: | NCT00045773 |
| Health Authority: | United States: Federal Government |
|
|
|
|